Effects of a Tissue Selective Estrogen Complex (TESC) on Depression and the Neural Reward System in the Perimenopause
Phase of Trial: Phase IV
Latest Information Update: 14 Jan 2019
Price : $35 *
At a glance
- Drugs Conjugated estrogens/bazedoxifene (Primary)
- Indications Major depressive disorder; Perimenopause
- Focus Pharmacodynamics
- 17 Dec 2018 Planned End Date changed from 1 Nov 2020 to 1 Dec 2020.
- 17 Dec 2018 Planned primary completion date changed from 1 Nov 2020 to 1 Dec 2020.
- 17 Dec 2018 Status changed from not yet recruiting to recruiting.